Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 19;15(1):5228.
doi: 10.1038/s41467-024-49547-9.

Palladium-catalyzed Suzuki-Miyaura cross-couplings of stable glycal boronates for robust synthesis of C-1 glycals

Affiliations

Palladium-catalyzed Suzuki-Miyaura cross-couplings of stable glycal boronates for robust synthesis of C-1 glycals

Anrong Chen et al. Nat Commun. .

Abstract

C-1 Glycals serve as pivotal intermediates in synthesizing diverse C-glycosyl compounds and natural products, necessitating the development of concise, efficient and user-friendly methods to obtain C-1 glycosides is essential. The Suzuki-Miyaura cross-coupling of glycal boronates is notable for its reliability and non-toxic nature, but glycal donor stability remains a challenge. Herein, we achieve a significant breakthrough by developing stable glycal boronates, effectively overcoming the stability issue in glycal-based Suzuki-Miyaura coupling. Leveraging the balanced reactivity and stability of our glycal boronates, we establish a robust palladium-catalyzed glycal-based Suzuki-Miyaura reaction, facilitating the formation of various C(sp2)-C(sp), C(sp2)-C(sp2), and C(sp2)-C(sp3) bonds under mild conditions. Notably, we expand upon this achievement by developing the DNA-compatible glycal-based cross-coupling reaction to synthesize various glycal-DNA conjugates. With its excellent reaction reactivity, stability, generality, and ease of handling, the method holds promise for widespread appication in the preparation of C-glycosyl compounds and natural products.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. The background and development of glycal-based Suzuki-Miyaura cross-coupling reactions.
a Selected nature products and drugs featuring C-glycosides. b Some selected synthetic transformations from glycals. c The research backgroud of glycal-based Suzuki-Miyaura coupling towards C-glycals. d Palladium-catalyzed Suzuki-Miyaura coupling of stable glycal boronates (our work). [B]: Borate esters. P: Protecting groups. [X]: Halogens or pseudohalogens. [FG]: Functional groups. C: Carbon electrophiles. Bpai: Pinanediol–boronic acid esters. BEpin: 1,1,2,2-Tetraethylethylene glycol–boronic acid esters.
Fig. 2
Fig. 2. Substrate scope of electrophilic reagents.
General reaction conditions: 12b (0.12 mmol), 14 (0.10 mmol), Pd(PPh3)2Cl2 (5.0 mol%), K3PO4 (3.0 equiv), DMF (2.0 mL), 33 °C, 48 h, N2, isolated yields. aMethyl 4-iodobenzoate was used. bMethyl 4-(trifluoromethylsulfonyloxy)benzoate was used. cNMR yields. TIPS: Triisopropylsilyl groups. [X]: Halogens or pseudohalogens. C: Carbon electrophiles. Bpai: Pinanediol–boronic acid esters.
Fig. 3
Fig. 3. Substrate scope of oligopeptide electrophilic reagents.
General reaction conditions: 12b (0.12 mmol), 16 (0.10 mmol), Pd(PPh3)2Cl2 (5.0 mol%), K3PO4 (3.0 equiv), DMF (2.0 mL), 33 °C, 48 h, N2, isolated yields. a50.0 mol% Pd(PPh3)2Cl2 was used. reaction conditions, showcasing the favorable balance of reactivity and stability exhibite by the glycal boronates and their potential for broader impacts. TIPS: Triisopropylsilyl groups. AA: Amino acids. Bpai: Pinanediol–boronic acid esters.
Fig. 4
Fig. 4. Scope with core structures of bioactive molecules and pharmaceuticals.
General reaction conditions: 12b (0.12 mmol), bioactive molecules or pharmaceuticals (0.10 mmol), Pd(PPh3)2Cl2 (5.0 mol%), K3PO4 (300.0 mol%), DMF (2.0 mL), 33 °C, 48 h, N2, isolated yields. a10.0 mol% Pd(PPh3)2Cl2 was used. bAryl iodine reagent were used. cTrifluoromethanesulfonates were used. TIPS: Triisopropylsilyl groups.
Fig. 5
Fig. 5. Substrate scope of glycal boronates.
Reaction conditions: 12 (0.12 mmol), 14 (0.10 mmol), Pd(PPh3)2Cl2 (5.0 mol%), K3PO4 (3.0 equiv), DMF (2.0 mL), 33 °C, 48 h, N2, isolated yields. [B]: Borate esters. P: Protecting groups. [X]: Halogens or pseudohalogens. C: Carbon electrophiles. Bpai: Pinanediol–boronic acid esters. BEpin: 1,1,2,2-Tetraethylethylene glycol–boronic acid esters. TIPS: Triisopropylsilyl groups. TBS: tert-Butyl dimethylsilyl groups.
Fig. 6
Fig. 6. The one-pot reaction involves the Ir-catalyzed borylation of glycal followed by the Pd-catalyzed Suzuki–Miyaura coupling.
Reaction conditions: 18 (0.18 mmol, 1.8 equiv), B2Pai2 (0.12 mmol, 1.2 equiv), [Ir(OMe)(cod)]2 (2.0 mol%), dtbbpy (4.0 mol%), n-octane (1.0 ml), 80 °C, 24 h, then 14 (0.10 mmol, 1.0 equiv), Pd(PPh3)2Cl2 (5.0 mol%), K3PO4 (3.0 equiv), DMF (2.0 mL), 33 °C, 48 h, N2, isolated yields. P: Protecting groups. TIPS: Triisopropylsilyl groups. TBS: tert-Butyl dimethylsilyl groups.
Fig. 7
Fig. 7. On-DNA glycal-based Suzuki–Miyaura coupling of (hetero)aryl halides.
Reaction conditions: DNA headpieces 19 (1.00 equiv), CsOH (100 equiv), glycal boronates 12 (250 equiv, 0.15 M in DMF: Dioxane: EtOH = 1: 1: 1), and sSphos-Pd-G2 (2.00 equiv), 90 °C, 1 h, the conversion was determinedby LC-MS. [B]: Borate esters. P: Protecting groups. [X]: Halogens or pseudohalogens. Bpai: Pinanediol–boronic acid esters. BEpin: 1,1,2,2-Tetraethylethylene glycol–boronic acid esters. TIPS: Triisopropylsilyl groups.
Fig. 8
Fig. 8. Late-stage glycodiversifications and total synthesis of pharmaceuticals and biologically active molecules.
a Synthesis of dapagliflozin. b Glycodiversification of triclosan and 17β-estradiol. c Diels-Alder cycloaddition with dieno-glycoside. d Total synthesis of tofogliflozin and its derivatives. See Supplementary Note 2.6 for experimental details. TIPS: Triisopropylsilyl groups.

Similar articles

Cited by

  • Zweifel olefination for C-glycosylation.
    Trauner F, Boutet B, Pilz F, Weber V, Didier D. Trauner F, et al. Commun Chem. 2024 Dec 21;7(1):306. doi: 10.1038/s42004-024-01339-4. Commun Chem. 2024. PMID: 39709475 Free PMC article.

References

    1. Yang Y, Yu B. Recent advances in the chemical synthesis of C-glycosides. Chem. Rev. 2017;117:12281–12356. doi: 10.1021/acs.chemrev.7b00234. - DOI - PubMed
    1. Kitamura K, Ando Y, Matsumoto T, Suzuki K. Total synthesis of aryl C-glycoside natural products: Strategies and tactics. Chem. Rev. 2018;118:1495–1598. doi: 10.1021/acs.chemrev.7b00380. - DOI - PubMed
    1. Cao X, et al. Carbohydrate-based drugs launched during 2000−2021. Acta Pharm. Sin. B. 2022;12:3783–3821. doi: 10.1016/j.apsb.2022.05.020. - DOI - PMC - PubMed
    1. Chao EC, Henry RR. SGLT2 inhibition - a novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 2010;9:551–559. doi: 10.1038/nrd3180. - DOI - PubMed
    1. Alshatwi AA. Catechin hydrate suppresses MCF−7 proliferation through TP53/caspase-mediated apoptosis. J. Exp. Clin. Cancer Res. 2010;29:167. doi: 10.1186/1756-9966-29-167. - DOI - PMC - PubMed